ArticleClinical rheumatology2010
Incidence of cancer among female patients with systemic lupus erythematosus in Korea.
Article in Clinical rheumatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 8 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Association Between Systemic Lupus Erythematosus and Cancer Morbidity and Mortality: Findings From Cohort Studies.Frontiers in oncology · 2022Pooled it
- The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.Arthritis research & therapy · 2018Pooled it
- No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.Clinical rheumatology · 2018Pooled it
- Pooled it
- A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus.Journal of cancer research and clinical oncology · 2014Pooled it
- Thyroid cancer in systemic lupus erythematosus: a meta analysis.International journal of clinical and experimental pathology · 2014Pooled it
- Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.Clinical rheumatology · 2011Pooled it
- Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis.British journal of cancer · 2011Pooled it
- Leucine, autoimmune diseases, and circulating mediators shape the causal landscape of lymphoid malignancies.Frontiers in immunology · 2026Article
- Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study.Arthritis research & therapy · 2025Article
- Risk of cancer and conventional syntethic DMARDS: A narrative review.Northern clinics of Istanbul · 2025Article
- Malignancy in systemic lupus erythematosus: relation to disease characteristics in 92 patients - a single center retrospective study.Rheumatology international · 2024Article
- Case report: Synchronous tumors of the female reproductive tract in systemic lupus erythematosus: report of two cases and review of the literature.Frontiers in oncology · 2024Article
- Epidemiology of systemic lupus erythematosus in Korea.Journal of rheumatic diseases · 2023Review
- [Management of inflammatory rheumatic diseases during and after malignancies].Zeitschrift fur Rheumatologie · 2022Article
- Causal effects of systemic lupus erythematosus on endometrial cancer: A univariable and multivariable Mendelian randomization study.Frontiers in oncology · 2022Article
- Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea.Arthritis research & therapy · 2021Article
- Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.PloS one · 2021Article
- Hormone-Related Cancer and Autoimmune Diseases: A Complex Interplay to be Discovered.Frontiers in genetics · 2021Review
- Malignancy in Systemic Lupus Erythematosus (SLE) PatientsAsian Pacific journal of cancer prevention : APJCP · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to ascertain the incidence of cancer in patients with systemic lupus erythematosus (SLE) in comparison with that in the general population in Korea, and to identify the cancer-types, the organ involvement, and the association with immunosuppressive therapy. The study subjects were consecutive SLE patients evaluated at Kangnam St. Mary's hospital between 1997 and 2007. The incidence rate of cancer was calculated and was analyzed in comparison to that of age- and sex-matched cohort obtained from the Korea National Cancer Registry. Nine hundred fourteen patients were observed for a total of 5,716 person-years. A total of 16 cases of cancer occurred. The average age at the diagnosis of cancer and the mean disease duration were 43 years and 11 years, respectively. The standardized incidence ratio (SIR) of all cancers was 1.45 (95% CI 0.74-2.16); The SIRs for the three most frequent cancers were 3.42 for cervix cancer (CI 0.00-7.26), 15.37 for non-Hodgkin's lymphoma (NHL; CI 2.90-37.68), and 43.55 for bladder cancer (CI 8.21-106.78). There were significant differences in the hematologic and renal involvement between SLE patients with cancer and without. Cyclophosphamide therapy, especially with cumulative dose more than 6 g (p = 0.017), seemed to contribute to the increased risk of cancer. Long disease duration, damage, and hematologic involvement were associated with increased risk of cancer occurrence. SLE patients are at high risk for NHL and bladder cancer. Active cancer screening is required in SLE patients with long disease duration and damage who are treated with high dose cyclophosphamide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.